Loading patent…
AssigneeACADIA Pharmaceuticals Inc.
InventorsAlex Nivorozhkin, Nelson Landrau
Estimating the term…
The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.
A substantially pure, isotopically-enriched compound of formula (I):
A pharmaceutically acceptable salt of an isotopically-enriched compound according to formula (I):
A tablet composition formulated for oral administration, comprising neuro-attenuating norketamine (NANKET).
A tablet composition formulated for oral administration, comprising neuro-attenuating ketamine (NAKET).
An isolated, isotopically-enriched neuro-attenuating norketamine (NANKET) compound or a pharmaceutically acceptable salt thereof.
The isolated, deuterium-enriched neuro-attenuating norketamine (NANKET) compound of claim 68, wherein the compound has the following structure:
An isolated, deuterium-enriched neuro-attenuating norketamine (NANKET) compound or a pharmaceutically acceptable salt thereof.
The isolated, deuterium-enriched neuro-attenuating norketamine (NANKET) compound of claim 68, wherein the compound has the following structure:
The pharmaceutical composition of claim 89, wherein the deuterium-enriched neuro-attenuating norketamine (NANKET) compound has the following structure:
A synthetic composition of matter comprising an isotopically-enriched neuro-attenuating norketamine (NANKET) compound or a pharmaceutically acceptable salt thereof.
A synthetic composition of matter comprising deuterium-enriched neuro-attenuating norketamine (NANKET) compound or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition for treating a subject diagnosed with, suffering from or susceptible to a disease, disorder or condition, such as those for which ketamine treatment may be indicated, wherein the subject is in need of the treatment, said pharmaceutical composition comprising:
A method for treating a subject diagnosed with, suffering from or susceptible to a disease, disorder or condition, such as those for which ketamine treatment may be indicated, wherein the subject is in need of the treatment, said method comprising:
An oral, modified-release pharmaceutical composition for oral administration to a subject for treating the subject diagnosed with, suffering from or susceptible to a disease, disorder or condition, such as those for which ketamine treatment may be indicated, considered or recommeded, wherein the subject is in need of treatment with said oral, modified-release pharmaceutical composition, said oral, modified-release pharmaceutical composition comprising:
An oral, modified-release pharmaceutical composition for oral administration to a subject for treating the subject diagnosed with, suffering from or susceptible to a disease, disorder or condition, such as those for which ketamine treatment may be indicated, considered or recommeded, wherein the subject is in need of treatment with said oral, modified-release pharmaceutical composition, said oral, modified-release pharmaceutical composition comprising:
An oral, modified-release pharmaceutical composition for oral administration to a subject for treating the subject diagnosed with, suffering from or susceptible to a disease, disorder or condition, such as those for which ketamine treatment may be indicated, considered or recommeded, wherein the subject is in need of treatment with said oral, modified-release pharmaceutical composition, said oral, modified-release pharmaceutical composition comprising:
Dependencies are inferred from the claim text.